Tag: antipsychotic drugs market

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Antipsychotic Drugs Market Size Outlook: How Quickly Will Revenue Expand Through 2030?

The antipsychotic drugs market has experienced robust growth in recent years. It is forecast to increase from $21.25 billion in 2025 to $23.23 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.3%. This historical expansion is largely due to the introduction of first-generation antipsychotics, a greater understanding of mental health disorders, the enhancement of hospital and clinical infrastructure, an uptick in the prevalence of schizophrenia and bipolar disorder, and elevated research and development investments in neuropsychiatric drugs.

The antipsychotic drugs market is set for substantial growth in the upcoming years. It is projected to expand to a size of $33.26 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 9.4%. This anticipated expansion during the forecast period is driven by factors such as advancements in atypical and partial dopamine agonists, the integration of precision medicine techniques, the adoption of AI in mental health diagnostics, the widening reach of online pharmacy distribution, and a greater emphasis on long-acting injectable formulations. Prominent trends expected in this period include personalized antipsychotic therapies, an increasing geriatric population, the rising prevalence of schizophrenia and bipolar disorder, the emergence of telepsychiatry and digital mental health platforms, and the continued development of long-acting injectable antipsychotics.

Get A Free Sample Report With In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18780&type=smp&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Antipsychotic Drugs Market Expansion Drivers: What’s Shaping Future Growth?

The increasing prevalence of mental disorders is anticipated to stimulate the expansion of the antipsychotic drug market in the future. Mental disorders, also referred to as mental illnesses, are conditions affecting an individual’s thought processes, conduct, emotional state, and overall mental well-being. Factors influencing instances of mental disorders include stress levels, societal pressures, genetic predispositions, biochemical imbalances, neurodevelopmental concerns, and existing physical health conditions. Antipsychotic drugs manage mental disorders through modifying the activity of neurotransmitters, chiefly dopamine and serotonin, thereby diminishing psychotic symptoms, steadying mood, and enhancing cognitive and emotional functions. For example, in November 2023, a survey by the Substance Abuse and Mental Health Services Administration (SAMHSA), a US public health agency, revealed that approximately 6% of adults aged 18 or older, amounting to 15.4 million people, reported serious mental illness (SMI). Additionally, in September 2024, the Australian Institute of Health and Welfare, an Australian government agency, projected that the population with dementia in Australia is anticipated to more than double from about 411,100 in 2023 to 849,300 by 2058, impacting approximately 315,500 men and 533,800 women. Consequently, the rising occurrence of mental disorders is fueling the antipsychotic drug market.

Antipsychotic Drugs Market Segment Breakdown: Which Categories Lead On Revenue?

The antipsychotic drugs market covered in this report is segmented –

1) By Therapeutic Class: First Generation, Second Generation, Third Generation

2) By Disease: Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, Other Diseases

3) By Distribution Channel: Hospital Pharmacies, Drug Stores, Online Pharmacies

Subsegments:

1) By First Generation: Typical Antipsychotics, Phenothiazines, Butyrophenones, Thioxanthenes, Dibenzoxazepines

2) By Second Generation: Atypical Antipsychotics, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripiprazole, Paliperidone, Lurasidone

3) By Third Generation: Partial Dopamine Agonists, Aripiprazole, Brexpiprazole, Cariprazine

Antipsychotic Drugs Market Strategic Trends: What Defines The Next Growth Phase?

Leading companies in the antipsychotic drug market are concentrating on developing advanced medical solutions, such as subcutaneous atypical antipsychotic injections, to achieve better patient adherence and enhanced efficacy compared to traditional oral treatments. These subcutaneous atypical antipsychotic injections are psychiatric medications administered beneath the skin to manage mental illnesses, maintain stable blood levels, and improve symptom control. For instance, in April 2023, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, and MedinCell SA, a France-based producer of biological products and pharmaceutical preparations, introduced UZEDY, which received U.S. Food and Drug Administration (FDA) approval. This product is an extended-release injectable formulation of risperidone, designed as a long-acting subcutaneous injection offering flexible dosing intervals of one or two months. UZEDY incorporates MedinCell’s proprietary SteadyTeq technology, ensuring a consistent release of the medication, reaching therapeutic levels within 6–24 hours of administration. Clinical trials demonstrated that UZEDY reduced the risk of schizophrenia relapse by up to an 80% compared to a placebo. Its purpose is to address adherence issues commonly linked with oral antipsychotics, which frequently result in relapse.

Antipsychotic Drugs Market Leading Players And Competitive Positioning

Major companies operating in the antipsychotic drugs market are Pfizer Inc., Johnson & Johnson Services Inc., Merck And Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Aurobindo Pharma Ltd., Cipla Ltd., H. Lundbeck A/S, Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., Apotex Inc., Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Alkermes plc

View The Full Antipsychotic Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/antipsychotic-drugs-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Antipsychotic Drugs Market Regional Analysis And Top Geography

North America was the largest region in the antipsychotic drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antipsychotic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Antipsychotic Drugs Market Growth From $23.23 Billion In 2026 To $33.25 Billion By 2030 At A CAGR Of 9.4%

The market for antipsychotic medications has experienced notable expansion over recent years. Projected to rise from $21.25 billion in 2025 to $23.23 billion in 2026, this represents a compound annual growth rate (CAGR) of 9.3%. Several factors fueled this historical growth, including the launch of first-generation antipsychotics, heightened awareness surrounding mental health conditions, the development of hospital and clinical facilities, an increasing incidence of schizophrenia and bipolar disorder, and greater investment in research and development for neuropsychiatric drugs.

The market for antipsychotic drugs is projected to experience significant expansion over the coming years, climbing to $33.26 billion by 2030 with a compound annual growth rate (CAGR) of 9.4%. Key factors driving this forecast period growth include innovations in atypical and partial dopamine agonists, the growing use of precision medicine, the application of artificial intelligence in mental health diagnosis, the rise of online pharmacy channels, and an increased emphasis on long-acting injectable medications. Noteworthy trends shaping this period involve the shift toward personalized antipsychotic treatments, a growing elderly population, higher rates of schizophrenia and bipolar disorder, the emergence of telepsychiatry and digital mental health services, and the advancement of long-acting injectable antipsychotics.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18780&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Antipsychotic Drugs Market Expansion Supported By Key Demand Factors

The rising prevalence of mental health conditions is anticipated to boost the expansion of the antipsychotic drug market in the coming years. Mental disorders, also referred to as mental illnesses, are conditions that influence an individual’s thoughts, behaviors, mood, and overall psychological well-being. These cases can stem from factors such as stress levels, societal expectations, genetic predisposition, biochemical imbalances, neurodevelopmental issues, and physical health problems. Antipsychotic medications manage mental disorders by modulating neurotransmitter activity, specifically dopamine and serotonin, which helps alleviate psychotic symptoms, stabilize mood, and enhance cognitive and emotional functioning. For example, a November 2023 survey by the Substance Abuse and Mental Health Services Administration (SAMHSA), a US public health agency, revealed that around 6% of adults aged 18 and older—approximately 15.4 million people—reported having a serious mental illness (SMI). Meanwhile, in September 2024, the Australian Institute of Health and Welfare, an Australian government agency, projected that the number of individuals living with dementia in Australia will rise from roughly 411,100 in 2023 to 849,300 by 2058, affecting about 315,500 men and 533,800 women. Consequently, the escalating occurrence of mental disorders is fueling growth in the antipsychotic drug market.

Antipsychotic Drugs Market Segment Analysis: What Are The Major Market Categories?

The antipsychotic drugs market covered in this report is segmented –

1) By Therapeutic Class: First Generation, Second Generation, Third Generation

2) By Disease: Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, Other Diseases

3) By Distribution Channel: Hospital Pharmacies, Drug Stores, Online Pharmacies

Subsegments:

1) By First Generation: Typical Antipsychotics, Phenothiazines, Butyrophenones, Thioxanthenes, Dibenzoxazepines

2) By Second Generation: Atypical Antipsychotics, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripiprazole, Paliperidone, Lurasidone

3) By Third Generation: Partial Dopamine Agonists, Aripiprazole, Brexpiprazole, Cariprazine

Antipsychotic Drugs Market Growth Trends Influencing Competitive Dynamics

Key players in the antipsychotic drug market are concentrating on the creation of cutting-edge medical solutions, including subcutaneous atypical antipsychotic injections, which aim to boost patient adherence and provide superior effectiveness when compared with conventional oral treatments. These subcutaneous injections, administered under the skin, are psychiatric medications used to manage mental health conditions, sustain consistent drug levels in the bloodstream, and enhance control over symptoms. A notable example occurred in April 2023, when Teva Pharmaceutical Industries Ltd., an Israeli pharmaceutical firm, partnered with MedinCell SA, a French manufacturer of biological products and pharmaceutical formulations, to debut UZEDY, which received approval from the U.S. Food and Drug Administration (FDA). This extended-release injectable formulation of risperidone, designed as a long-acting subcutaneous shot, offers adaptable dosing every one or two months. UZEDY leverages MedinCell’s proprietary SteadyTeq technology, guaranteeing a gradual medication release that achieves therapeutic concentrations within 6 to 24 hours after administration. During clinical studies, UZEDY was found to lower the risk of schizophrenia relapse by up to 80% relative to a placebo. It is specifically aimed at overcoming compliance challenges often seen with oral antipsychotics, which frequently result in relapse.

Antipsychotic Drugs Market Leading Companies Driving Competitive Growth

Major companies operating in the antipsychotic drugs market are Pfizer Inc., Johnson & Johnson Services Inc., Merck And Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Aurobindo Pharma Ltd., Cipla Ltd., H. Lundbeck A/S, Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., Apotex Inc., Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Alkermes plc

Access The Complete Antipsychotic Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/antipsychotic-drugs-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Antipsychotic Drugs Market Regional Distribution: Which Areas Drive Market Expansion?

North America was the largest region in the antipsychotic drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antipsychotic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Antipsychotic Drugs Market Progress Between 2026 And 2030?

The antipsychotic drugs market size has demonstrated significant expansion in recent years. It is anticipated to increase from $21.25 billion in 2025 to $23.23 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.3%. This historical growth can be ascribed to the emergence of first-generation antipsychotics, heightened awareness of mental health disorders, the enlargement of hospital and clinical infrastructure, the escalating prevalence of schizophrenia and bipolar disorder, and augmented r&d investments in neuropsychiatric drugs.

The antipsychotic drugs market is anticipated to show robust expansion over the coming years, reaching $33.26 billion by 2030, with a compound annual growth rate (CAGR) of 9.4%. This expected growth during the forecast period stems from advancements in atypical and partial dopamine agonists, the adoption of precision medicine approaches, the integration of AI in mental health diagnostics, the expansion of online pharmacy distribution channels, and a heightened focus on long-acting injectable formulations. Prominent trends within this forecast period include personalized antipsychotic therapy, an increasing geriatric population, the rising prevalence of schizophrenia and bipolar disorder, the widespread use of telepsychiatry and digital mental health platforms, and the continued development of long-acting injectable antipsychotics.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18780&type=smp

Which Primary Drivers Are Impacting The Antipsychotic Drugs Market Growth?

The rising occurrence of mental disorders is projected to fuel the expansion of the antipsychotic drug market in the future. These conditions, frequently termed mental illnesses, are health issues that affect an individual’s thoughts, actions, feelings, and overall mental well-being. Various factors, including stress levels, societal pressures, genetic predisposition, biochemical imbalance, neurodevelopmental issues, and physical health conditions, can influence instances of mental disorders. Antipsychotic medications manage mental disorders by modifying the activity of neurotransmitters, chiefly dopamine and serotonin, thereby diminishing psychotic symptoms, stabilizing mood, and enhancing cognitive and emotional function. For example, in November 2023, data from a survey by the Substance Abuse and Mental Health Services Administration (SAMHSA), a US-based government public health agency, indicated that roughly 6% of adults aged 18 or older, totaling 15.4 million people, reported experiencing serious mental illness (SMI). Additionally, in September 2024, the Australian Institute of Health and Welfare, an Australia-based government agency, forecast that the number of people living with dementia in Australia is anticipated to more than double from approximately 411,100 in 2023 to 849,300 by 2058. This surge is expected to impact around 315,500 men and 533,800 women. Consequently, the increasing prevalence of mental disorders is propelling the antipsychotic drug market.

How Is The Antipsychotic Drugs Market Organized By Segment Classification?

The antipsychotic drugs market covered in this report is segmented –

1) By Therapeutic Class: First Generation, Second Generation, Third Generation

2) By Disease: Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, Other Diseases

3) By Distribution Channel: Hospital Pharmacies, Drug Stores, Online Pharmacies

Subsegments:

1) By First Generation: Typical Antipsychotics, Phenothiazines, Butyrophenones, Thioxanthenes, Dibenzoxazepines

2) By Second Generation: Atypical Antipsychotics, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripiprazole, Paliperidone, Lurasidone

3) By Third Generation: Partial Dopamine Agonists, Aripiprazole, Brexpiprazole, Cariprazine

What Trends Are Transforming The Antipsychotic Drugs Market?

Key companies in the antipsychotic drug market are focusing on developing advanced medical products, such as subcutaneous atypical antipsychotic injections, to provide improved patient compliance and enhanced efficacy compared to traditional oral medications. Subcutaneous atypical antipsychotic injections are psychiatric medications delivered under the skin to treat mental illnesses, maintain stable blood levels, and improve symptom control. For example, in April 2023, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, along with MedinCell SA, a France-based manufacturer of biological products and pharmaceutical preparations, introduced U.S. Food and Drug Administration (FDA)-approved UZEDY. This product is an extended-release injectable risperidone formulation, designed as a long-acting subcutaneous injection, offering flexible dosing intervals of one or two months. UZEDY employs MedinCell’s proprietary SteadyTeq technology, which ensures a steady release of the medication, reaching therapeutic levels within 6–24 hours of administration. Clinical trials showed that UZEDY led to up to an 80% reduction in the risk of schizophrenia relapse compared to placebo. It aims to address adherence challenges frequently associated with oral antipsychotics, which often contribute to relapse.

Who Are The Industry Participants Involved In The Antipsychotic Drugs Market?

Major companies operating in the antipsychotic drugs market are Pfizer Inc., Johnson & Johnson Services Inc., Merck And Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Aurobindo Pharma Ltd., Cipla Ltd., H. Lundbeck A/S, Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., Apotex Inc., Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Alkermes plc

Get The Full Antipsychotic Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/antipsychotic-drugs-global-market-report

Which Region Dominates The Antipsychotic Drugs Market By Market Share?

North America was the largest region in the antipsychotic drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antipsychotic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Antipsychotic Drugs Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/antipsychotic-drugs-global-market-report

Browse Through More Reports Similar to the Global Antipsychotic Drugs Market 2026, By The Business Research Company

Antipsychotic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/antipsychotic-drugs-global-market-report

Anticholinergic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anticholinergic-drugs-global-market-report

Epilepsy Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/epilepsy-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Antipsychotic Drugs Market From 2026 To 2030?

The antipsychotic drugs market size has experienced robust growth over recent years. It is projected to expand from $21.25 billion in 2025 to $23.23 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.3%. This historical growth can be linked to factors such as the introduction of first-generation antipsychotics, a rising awareness of mental health disorders, the expansion of hospital and clinical infrastructure, an increasing prevalence of schizophrenia and bipolar disorder, and enhanced research and development investments in neuropsychiatric drugs.

The antipsychotic drugs market is projected to experience substantial expansion in the coming years, with its size anticipated to reach $33.26 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.4%. This projected growth is primarily driven by several factors, including progress in atypical and partial dopamine agonists, the increasing adoption of precision medicine approaches, the integration of AI in mental health diagnostics, the expansion of online pharmacy distribution, and a heightened focus on long-acting injectable formulations. Key trends influencing this forecast period encompass personalized antipsychotic therapy, a rising geriatric population, the increasing prevalence of schizophrenia and bipolar disorder, the emergence of telepsychiatry and digital mental health platforms, and the continued development of long-acting injectable antipsychotics.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18780&type=smp

What Drivers Are Influencing The Antipsychotic Drugs Market?

The antipsychotic drug market is anticipated to expand due to the increasing occurrence of mental disorders. These illnesses, which affect a person’s thoughts, actions, feelings, and overall mental well-being, can stem from factors such as stress, societal pressures, genetic tendencies, biochemical imbalances, neurodevelopmental issues, and physical health. Antipsychotic medications address mental disorders by modifying neurotransmitter activity, particularly dopamine and serotonin, which helps in alleviating psychotic symptoms, stabilizing mood, and enhancing cognitive and emotional capabilities. For example, a survey by SAMHSA, a US public health agency, indicated in November 2023 that roughly 6% of adults aged 18 or older, amounting to 15.4 million people, experienced serious mental illness (SMI). Additionally, the Australian Institute of Health and Welfare, an Australian government body, reported in September 2024 that the number of individuals with dementia in Australia is projected to more than double from approximately 411,100 in 2023 to 849,300 by 2058, impacting around 315,500 men and 533,800 women. Thus, the rising incidence of mental disorders is a key driver for the antipsychotic drug market.

Which Segments Are Included In The Analysis Of The Antipsychotic Drugs Market?

The antipsychotic drugs market covered in this report is segmented –

1) By Therapeutic Class: First Generation, Second Generation, Third Generation

2) By Disease: Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, Other Diseases

3) By Distribution Channel: Hospital Pharmacies, Drug Stores, Online Pharmacies

Subsegments:

1) By First Generation: Typical Antipsychotics, Phenothiazines, Butyrophenones, Thioxanthenes, Dibenzoxazepines

2) By Second Generation: Atypical Antipsychotics, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripiprazole, Paliperidone, Lurasidone

3) By Third Generation: Partial Dopamine Agonists, Aripiprazole, Brexpiprazole, Cariprazine

Which Trends Are Impacting The Growth Of The Antipsychotic Drugs Market?

Leading companies in the antipsychotic drug market are prioritizing the creation of advanced medical products, such as subcutaneous atypical antipsychotic injections, with the aim of boosting patient compliance and improving efficacy over traditional oral medications. These subcutaneous atypical antipsychotic injections are psychiatric medicines given under the skin to treat mental illnesses, maintain stable blood levels, and enhance symptom control. For instance, in April 2023, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, and MedinCell SA, a France-based manufacturer of biological products and pharmaceutical preparations, introduced U.S. Food and Drug Administration (FDA)-approved UZEDY. This product is an extended-release injectable formulation of risperidone, engineered as a long-acting subcutaneous injection that provides flexible dosing intervals of one or two months. UZEDY employs MedinCell’s proprietary SteadyTeq technology, which guarantees a consistent release of the medication, reaching therapeutic levels within 6–24 hours of administration. Clinical trials indicated that UZEDY offered up to an 80% reduction in the risk of schizophrenia relapse compared to placebo. Its purpose is to resolve adherence challenges commonly linked with oral antipsychotics, which frequently contribute to relapse.

Which Key Industry Participants Are Active In The Antipsychotic Drugs Market?

Major companies operating in the antipsychotic drugs market are Pfizer Inc., Johnson & Johnson Services Inc., Merck And Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Aurobindo Pharma Ltd., Cipla Ltd., H. Lundbeck A/S, Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., Apotex Inc., Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Alkermes plc

Read the full antipsychotic drugs market report here:

https://www.thebusinessresearchcompany.com/report/antipsychotic-drugs-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Antipsychotic Drugs Market?

North America was the largest region in the antipsychotic drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antipsychotic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Antipsychotic Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=18780&type=smp

Browse Through More Reports Similar to the Global Antipsychotic Drugs Market 2026, By The Business Research Company

Antipsychotic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/antipsychotic-drugs-global-market-report

Anticholinergic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anticholinergic-drugs-global-market-report

Epilepsy Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/epilepsy-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the antipsychotic drugs market from 2026–2035 with trusted insights from The Business Research Company

Across 2026–2030, what is the expected market valuation path of the Antipsychotic Drugs Market?

The antipsychotic drugs market size has experienced robust growth in recent years. This market is projected to expand from $21.25 billion in 2025 to $23.23 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.3%. Key factors contributing to this historical expansion include the emergence of first-generation antipsychotics, increased understanding of mental health conditions, the development of hospital and clinical facilities, an uptick in the incidence of schizophrenia and bipolar disorder, and enhanced research and development spending on neuropsychiatric medications.

The market for antipsychotic drugs is projected to experience robust expansion in the coming years. This market is set to reach a value of $33.26 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.4%. The anticipated growth during this period is fueled by several factors, including progress in atypical and partial dopamine agonists, the embrace of precision medicine strategies, the incorporation of AI into mental health diagnostics, the widening reach of online pharmacy distribution, and a heightened emphasis on long-acting injectable formulations. Key trends anticipated during the forecast encompass personalized antipsychotic treatment, the growing elderly demographic, a higher incidence of schizophrenia and bipolar disorder, the rise of telepsychiatry and digital mental health platforms, and the ongoing development of long-acting injectable antipsychotics.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18780&type=smp

Which Drivers Are Supporting The Rise Of The Antipsychotic Drugs Market?

The increasing prevalence of mental disorders is anticipated to fuel the expansion of the antipsychotic drug market in the future. Mental disorders, also known as mental illnesses, are conditions that affect an individual’s thoughts, actions, mood, and overall mental health. Instances of mental disorders can be influenced by stress levels, societal pressures, genetic predisposition, biochemical imbalances, neurodevelopmental issues, and various physical health conditions. Antipsychotic drugs work to manage mental disorders by modifying the activity of neurotransmitters, mainly dopamine and serotonin, to alleviate psychotic symptoms, stabilize mood, and enhance both cognitive and emotional function. For example, a survey conducted in November 2023 by the Substance Abuse and Mental Health Services Administration (SAMHSA), a US-based government public health agency, found that approximately 6% of adults aged 18 or older, totaling 15.4 million individuals, reported experiencing serious mental illness (SMI). Furthermore, in September 2024, the Australian Institute of Health and Welfare, an Australia-based government agency, projected that the number of people living with dementia in Australia is expected to more than double from around 411,100 in 2023 to 849,300 by 2058. This surge will affect approximately 315,500 men and 533,800 women. Hence, the rising incidence of mental disorders is a key driver for the antipsychotic drug market.

What Leading Segments Are Studied In The Antipsychotic Drugs Market?

The antipsychotic drugs market covered in this report is segmented –

1) By Therapeutic Class: First Generation, Second Generation, Third Generation

2) By Disease: Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, Other Diseases

3) By Distribution Channel: Hospital Pharmacies, Drug Stores, Online Pharmacies

Subsegments:

1) By First Generation: Typical Antipsychotics, Phenothiazines, Butyrophenones, Thioxanthenes, Dibenzoxazepines

2) By Second Generation: Atypical Antipsychotics, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripiprazole, Paliperidone, Lurasidone

3) By Third Generation: Partial Dopamine Agonists, Aripiprazole, Brexpiprazole, Cariprazine

Which Innovation Trends Are Advancing Developments Within The Antipsychotic Drugs Market?

Major companies operating in the antipsychotic drug market are focusing on creating advanced medical products, including subcutaneous atypical antipsychotic injections, to offer better patient compliance and enhanced effectiveness compared to traditional oral medications. These subcutaneous atypical antipsychotic injections are psychiatric drugs given under the skin to treat mental illnesses, sustain stable blood levels, and improve symptom management. For example, in April 2023, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, and MedinCell SA, a France-based manufacturer of biological products and pharmaceutical preparations, launched U.S. Food and Drug Administration (FDA)-approved UZEDY. This product is an extended-release injectable formulation of risperidone, developed as a long-acting subcutaneous injection that allows flexible dosing intervals of one or two months. UZEDY utilizes MedinCell’s proprietary SteadyTeq technology, which guarantees a consistent release of the medication, reaching therapeutic levels within 6–24 hours of administration. In clinical trials, UZEDY demonstrated up to an 80% reduction in the risk of schizophrenia relapse compared to placebo. Its purpose is to address adherence problems commonly linked with oral antipsychotics, which often lead to a recurrence of symptoms.

Which Major Industry Participants Are Leading The Antipsychotic Drugs Market Growth?

Major companies operating in the antipsychotic drugs market are Pfizer Inc., Johnson & Johnson Services Inc., Merck And Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Aurobindo Pharma Ltd., Cipla Ltd., H. Lundbeck A/S, Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., Apotex Inc., Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Alkermes plc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/antipsychotic-drugs-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Antipsychotic Drugs Market?

North America was the largest region in the antipsychotic drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antipsychotic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Antipsychotic Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=18780&type=smp

Browse Through More Reports Similar to the Global Antipsychotic Drugs Market 2026, By The Business Research Company

Antipsychotic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/antipsychotic-drugs-global-market-report

Anticholinergic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anticholinergic-drugs-global-market-report

Epilepsy Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/epilepsy-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the antipsychotic drugs market from 2025–2034 with trusted insights from The Business Research Company

What Is The Current Size And Expected Growth Outlook For The Antipsychotic Drugs Market?

The antipsychotic drugs market has experienced robust growth in recent years. It is projected to expand from $19.5 billion in 2024 to $21.25 billion in 2025, achieving a compound annual growth rate (CAGR) of 9.0%. The historical growth of this market can be attributed to the increasing prevalence of mental health disorders, the development of second-generation antipsychotics, an expanding geriatric population, enhancements in healthcare infrastructure, and substantial investment in research and development.

The antipsychotic drugs market is projected to experience substantial expansion in the coming years. It is forecast to reach $30.39 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 9.4%. This anticipated growth during the forecast period is driven by several factors, including the rising occurrence of schizophrenia and bipolar disorder, favorable government policies and financial support, an increasing need for personalized medicine, efforts to minimize side effects, and the expansion of mental health advocacy and support organizations. Key trends anticipated for this period encompass the incorporation of digital health tools for monitoring, the creation of new mechanisms of action, a heightened emphasis on combination therapies, the use of pharmacogenomics for customized treatments, and a focus on drug development centered around patients.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18780&type=smp

Which Growth Drivers Are Propelling The Antipsychotic Drugs Market?

The escalating prevalence of mental disorders is projected to advance the antipsychotic drug market in the future. These conditions, also referred to as mental illnesses, are health issues that affect an individual’s thoughts, conduct, emotional state, and overall mental well-being. Factors such as stress levels, societal pressures, genetic predisposition, biochemical imbalance, neurodevelopmental issues, and physical health conditions can influence instances of mental disorders. Antipsychotic medications manage mental disorders by modulating the activity of neurotransmitters, chiefly dopamine and serotonin, thereby diminishing psychotic symptoms, stabilizing mood, and enhancing cognitive and emotional functions. For example, a survey by the Substance Abuse and Mental Health Services Administration (SAMHSA), a US-based public health agency, indicated that in November 2023, about 6% of adults aged 18 or older, totaling 15.4 million individuals, reported experiencing serious mental illness (SMI). Additionally, the Australian Institute of Health and Welfare, an Australia-based government body, stated in September 2024 that the population living with dementia in Australia is anticipated to more than double from approximately 411,100 in 2023 to 849,300 by 2058. This rise is expected to impact roughly 315,500 men and 533,800 women. Consequently, the increasing occurrence of mental disorders is fueling the antipsychotic drug market.

Which Segmentation Factors Are Most Significant In The Antipsychotic Drugs Market Analysis?

The antipsychotic drugs market covered in this report is segmented –

1) By Therapeutic Class: First Generation, Second Generation, Third Generation

2) By Disease: Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, Other Diseases

3) By Distribution Channel: Hospital Pharmacies, Drug Stores, Online Pharmacies

Subsegments:

1) By First Generation: Typical Antipsychotics, Phenothiazines, Butyrophenones, Thioxanthenes, Dibenzoxazepines

2) By Second Generation: Atypical Antipsychotics, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripiprazole, Paliperidone, Lurasidone

3) By Third Generation: Partial Dopamine Agonists, Aripiprazole, Brexpiprazole, Cariprazine

What New Opportunities Are Emerging From Trends In The Antipsychotic Drugs Market?

Major companies operating in the antipsychotic drug market are focused on developing advanced medical products, such as subcutaneous atypical antipsychotic injections, to offer improved patient compliance and enhanced efficacy compared to traditional oral medications. Subcutaneous atypical antipsychotic injections are psychiatric drugs that are given under the skin to treat mental illnesses, maintain stable blood levels, and improve symptom control. For instance, in April 2023, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, and MedinCell SA, a France-based manufacturer of biological products and pharmaceutical preparations, launched U.S. Food and Drug Administration (FDA)-approved UZEDY. It is an extended-release injectable formulation of risperidone designed as a long-acting subcutaneous injection that offers flexible dosing intervals of one or two months. UZEDY utilizes MedinCell’s proprietary SteadyTeq technology, which ensures a steady release of the medication, reaching therapeutic levels within 6–24 hours of administration. In clinical trials, UZEDY demonstrated up to an 80% reduction in the risk of schizophrenia relapse compared to placebo. It is intended to address adherence issues commonly associated with oral antipsychotics, which often lead to relapse.

Who Are The Most Influential Companies In The Antipsychotic Drugs Market?

Major companies operating in the antipsychotic drugs market are Pfizer Inc., Johnson & Johnson Services Inc., Merck And Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Aurobindo Pharma Ltd., Cipla Ltd., H. Lundbeck A/S, Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., Apotex Inc., Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Alkermes plc

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/antipsychotic-drugs-global-market-report

Which Region Holds The Largest Share In The Antipsychotic Drugs Market Today?

North America was the largest region in the antipsychotic drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antipsychotic drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=18780&type=smp

Browse Through More Reports Similar to the Global Antipsychotic Drugs Market 2025, By The Business Research Company

Acne Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/acne-drugs-global-market-report

Drugs For Immunotherapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/drugs-for-immunotherapy-global-market-report

Skin Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Predicted Market Size Of The Antipsychotic Drugs Industry By 2029?

The market for antipsychotic drugs has seen robust growth in the past few years and is projected to expand from a value of $19.5 billion in 2024 to $21.25 billion in 2025, with a compound annual growth rate (CAGR) of 9.0%. Factors contributing to growth during the historical period include an increase in mental health disorders, the creation of second-generation antipsychotics, a rise in the elderly population, enhancements to healthcare infrastructure, and substantial research and development investments.

In the coming years, the market size for antipsychotic drugs is predicted to experience significant growth, potentially reaching “$30.39 billion by 2029 with a compound annual growth rate (CAGR) of 9.4%. This expected development during the forecast period can be linked to a rise in cases of schizophrenia and bipolar disorder, encouraging government policies and funding, a surge in the need for individualized medication, a concentration on minimizing side effects, and the expansion of mental health advocacy and support groups. The forecast period is likely to see key trends such as the incorporation of digital health tools for surveillance, the creation of groundbreaking mechanisms of action, a heightened attention to combined therapies, the application of pharmacogenomics for customized treatments, and a focus on patient-centric drug development.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18780&type=smp

What Market Forces Are Contributing To The Growth Of The Antipsychotic Drugs Market?

Advancement within the antipsychotic drug market is projected to be propelled by the rising prevalence of mental disorders. Typically, mental illnesses refer to ailments that significantly impact an individual’s thought processes, behavioral patterns, mood, and mental health. Various factors such as stress, societal pressure, inherent genetic tendencies, neurodevelopmental problems, biochemical imbalances, and physical health conditions can contribute to mental disorders. Antipsychotic medications address these issues by manipulating the activities of neurotransmitters – primarily dopamine and serotonin – which in return mitigate psychotic symptoms, stability mood, and augment cognitive and emotional function. For example, the Substance Abuse and Mental Health Services Administration (SAMHSA), a US-based public health organisation, found in a survey held in November 2023 that approximately 6% of adults, or about 15.4 million people aged 18 and older, reported experiencing serious mental illness (SMI). Subsequently, the Australian Institute of Health and Welfare declared in September 2024 that the number of Australians living with dementia is predicted to more than double from approximately 411,100 in 2023 to 849,300 by 2058, affecting an estimated 315,500 men and 533,800 women. Consequently, the escalating prevalence of mental disorders is attributing to the growth of the antipsychotic drug market.

Which Segments Define The Structure Of The Antipsychotic Drugs Market?

The antipsychotic drugs market covered in this report is segmented –

1) By Therapeutic Class: First Generation, Second Generation, Third Generation

2) By Disease: Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, Other Diseases

3) By Distribution Channel: Hospital Pharmacies, Drug Stores, Online Pharmacies

Subsegments:

1) By First Generation: Typical Antipsychotics, Phenothiazines, Butyrophenones, Thioxanthenes, Dibenzoxazepines

2) By Second Generation: Atypical Antipsychotics, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripiprazole, Paliperidone, Lurasidone

3) By Third Generation: Partial Dopamine Agonists, Aripiprazole, Brexpiprazole, Cariprazine

What Strategic Shifts And Innovations Are Influencing The Antipsychotic Drugs Market?

Key players in the antipsychotic drug market are directing their efforts towards the production of innovative healthcare goods, such as atypical antipsychotic injectables to be administered subcutaneously. These solutions not only provide increased efficiency over conventional orally-taken medicines but also foster better patient compliance. Atypical antipsychotic injections administered beneath the skin serve as effective medications for mental disorders, helping to maintain level blood conditions and enhance symptom management. For instance, in April 2023, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical organization, teamed up with MedinCell SA, a French producer of biological and pharmaceutical products, to introduce UZEDY, a product that has received approval from U.S. Food and Drug Administration (FDA). UZEDY, an extended-release injectable variant of risperidone, is devised as a long-lasting subcutaneous injection capable of flexible administration intervals of one or two months. MedinCell’s exclusive SteadyTeq technology used in UZEDY ensures the steady dispersion of the drug, achieving therapeutic levels between 6-24 hours after injection. UZEDY displayed an up to 80% decrease in the probability of schizophrenia relapse in contrast with a placebo during clinical tests. The purpose of this drug is to deal with common adherence problems linked with oral antipsychotic medication, which frequently result in relapse.

Who Are The Most Influential Companies In The Antipsychotic Drugs Market?

Major companies operating in the antipsychotic drugs market are Pfizer Inc., Johnson & Johnson Services Inc., Merck And Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Aurobindo Pharma Ltd., Cipla Ltd., H. Lundbeck A/S, Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., Apotex Inc., Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Alkermes plc

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/antipsychotic-drugs-global-market-report

Which Region Is Forecasted To Lead The Antipsychotic Drugs Market In The Coming Years?

North America was the largest region in the antipsychotic drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antipsychotic drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=18780&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Does the Forecast Indicate for the Antipsychotic Drugs Market From 2025 to 2029?

There has been substantial growth in the size of the antipsychotic drugs market in the recent past. The market is projected to escalate from $19.5 billion in 2024 to $21.25 billion in 2025, yielding a compound annual growth rate (CAGR) of 9.0%. This historic growth is due to a surge in mental health disorders, development of second-generation antipsychotics, an expanding elderly population, enhancements in healthcare facilities, and significant investment in research and development.

The market for antipsychotic drugs is expected to experience robust growth in the coming years, projecting to reach $30.39 billion in 2029 with a compound annual growth rate (CAGR) of 9.4%. The surge in this projected period can be linked to the rising cases of schizophrenia and bipolar disorder, along with progressive government policies and funding. Increasing preferences for personalized medications, aiming to minimize side effects, and the growth of mental health activism and support groups also contribute. The horizon period will see key trends such as the integration of digital health monitoring tools, breakthrough developments in mechanisms of action, a heightened focus on combined therapies, the usage of pharmacogenomics for custom treatments, and a patient-focused approach towards drug development.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18780&type=smp

What Elements Are Contributing To Growth In The Antipsychotic Drugs Market?

The rise in mental health disorders is predicted to fuel the expansion of the antipsychotic drug market. Mental illnesses can significantly influence an individual’s thought processes, behavior, emotions, and overall mental health. These disorders can result from a variety of factors, including stress, societal expectations, inherited traits, chemical imbalances in the brain, developmental issues within the nervous system, and physical health problems. Antipsychotic medications work by modifying the functions of neurotransmitters, primarily dopamine and serotonin, to alleviate psychotic symptoms, stabilize emotions, and enhance cognitive and emotional performances. For example, a survey by the Substance Abuse and Mental Health Services Administration (SAMHSA), a US-based public health government agency, revealed that nearly 6% of adults over 18 years old, amounting to 15.4 million people, reported serious mental illness (SMI) in November 2023. Moreover, in September 2024, the Australian Institute of Health and Welfare projected that the number of people with dementia in Australia will more than double, from about 411,100 in 2023 to 849,300 by 2058, impacting about 315,500 men and 533,800 women. Consequently, the escalating incidence of mental health disorders is driving the growth of the antipsychotic drug market.

The antipsychotic drugs market covered in this report is segmented –

1) By Therapeutic Class: First Generation, Second Generation, Third Generation

2) By Disease: Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, Other Diseases

3) By Distribution Channel: Hospital Pharmacies, Drug Stores, Online Pharmacies

Subsegments:

1) By First Generation: Typical Antipsychotics, Phenothiazines, Butyrophenones, Thioxanthenes, Dibenzoxazepines

2) By Second Generation: Atypical Antipsychotics, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripiprazole, Paliperidone, Lurasidone

3) By Third Generation: Partial Dopamine Agonists, Aripiprazole, Brexpiprazole, Cariprazine

What Notable Trends Are Shaping The Direction Of The Antipsychotic Drugs Market?

Leading businesses in the antipsychotic drug market are endeavouring to create enhanced medical solutions, such as subcutaneous atypical antipsychotic injections. These innovative drugs are designed to provide superior patient adherence and increased efficiency than conventional oral drugs. Administered beneath the skin, these powerful injectable psychiatric medications are designed to manage mental disorders better, maintain steady blood levels, and amplify symptom control. For instance, in April 2023, Teva Pharmaceutical Industries Ltd., hailing from Israel, and France’s MedinCell SA, a biological product, and pharmaceutical manufacturer, initiated the launch of the U.S. FDA-approved UZEDY. It’s created as a risperidone extended-release injectable formulation, intended as a subcutaneous injection applicable for long periods, offering one to two months flexible dosing intervals. UZEDY, powered by MedinCell’s proprietary SteadyTeq technology, guarantees a balanced medication release, achieving therapeutic levels within just 6–24 hours of administration. Clinical trials highlighted UZEDY’s effectiveness, displaying an up to 80% reduction in schizophrenia relapse risk compared to placebo. It is designed to rectify adherence complications often linked with oral antipsychotics, typically causing relapses.

Who Are The Key Contributors To Growth In The Antipsychotic Drugs Market?

Major companies operating in the antipsychotic drugs market are Pfizer Inc., Johnson & Johnson Services Inc., Merck And Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Aurobindo Pharma Ltd., Cipla Ltd., H. Lundbeck A/S, Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., Apotex Inc., Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Alkermes plc

https://www.thebusinessresearchcompany.com/report/antipsychotic-drugs-global-market-report

Which Region Is Projected To Lead The Antipsychotic Drugs Market By 2025?

North America was the largest region in the antipsychotic drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antipsychotic drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=18780&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What Are the Key Projections for the CAGR of the Antipsychotic Drugs Market Size From 2025 to 2034?#_x000D_

The market for antipsychotic medications has seen substantial expansion in the past few years. The market would escalate from $19.5 billion in 2024 to $21.25 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 9.0%. The significant growth witnessed in the past can be credited to the increasing incidence of mental health conditions, the emergence of second-generation antipsychotics, an expanding older population, enhancements in healthcare facilities, and substantial investment in research and development._x000D_

_x000D_

The market for antipsychotic drugs is anticipated to experience notable growth in the coming years. It’s projected to reach a value of $30.39 billion in 2029, with a compound annual growth rate (CAGR) of 9.4%. Factors contributing to this growth during the forecasted period include the rising prevalence of schizophrenia and bipolar disorder, favorable government policies and support, an increase in the demand for customized medicine, a focus on diminishing side effects, and the rise of mental health advocacy and support communities. Key trends during this forecast period comprise the incorporation of digital health tools for patient monitoring, introduction of new mechanisms of action, greater emphasis on combination therapies, application of pharmacogenomics in offering personalized treatments, and a focus on developing drugs with a patient-centered approach._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=18780&type=smp_x000D_

_x000D_

#Which Major Market Drivers Are Expected to Boost the Growth Potential of the Antipsychotic Drugs Market?#_x000D_

The escalating prevalence of mental illnesses is predicted to fuel the expansion of the antipsychotic drug market. These illnesses, frequently referred to as mental disorders, are conditions that influence an individual’s cognitive processes, actions, moods, and mental wellbeing. Factors such as societal stressors, genetic susceptibility, biochemical imbalances, neurodevelopmental complications, and physical health conditions can contribute to cases of mental disorder. Antipsychotic medications manage mental disorders by modifying neurotransmitter activity, mainly dopamine and serotonin, in order to alleviate psychotic symptoms, balance mood, and enhance cognitive and emotional functionality. For example, as per a survey by the Substance Abuse and Mental Health Services Administration (SAMHSA), a US public health government agency, in November 2023, roughly 6% of adults aged 18 years and above, equating to 15.4 million individuals, were found to suffer from severe mental illness (SMI). Additionally, as per the Australian Institute of Health and Welfare, a government agency in Australia, in September 2024, the count of individuals afflicted with dementia in Australia is projected to more than double from nearly 411,100 in 2023 to 849,300 by the year 2058. This surge will impact approximately 315,500 men and 533,800 women. Hence, the increasing prevalence of mental illnesses is stimulating the growth of the antipsychotic medication market._x000D_

_x000D_

#Which Key Market Segments Comprise the Antipsychotic Drugs Market and Drive Its Revenue Growth?#_x000D_

The antipsychotic drugs market covered in this report is segmented – _x000D_

_x000D_

1) By Therapeutic Class: First Generation, Second Generation, Third Generation_x000D_

2) By Disease: Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, Other Diseases_x000D_

3) By Distribution Channel: Hospital Pharmacies, Drug Stores, Online Pharmacies_x000D_

_x000D_

Subsegments:_x000D_

1) By First Generation: Typical Antipsychotics, Phenothiazines, Butyrophenones, Thioxanthenes, Dibenzoxazepines _x000D_

2) By Second Generation: Atypical Antipsychotics, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripiprazole, Paliperidone, Lurasidone _x000D_

3) By Third Generation: Partial Dopamine Agonists, Aripiprazole, Brexpiprazole, Cariprazine_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=18780&type=smp_x000D_

_x000D_

#Which Areas Are Leading Regions in the Antipsychotic Drugs Market Expansion Across the Globe?#_x000D_

North America was the largest region in the antipsychotic drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antipsychotic drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Are the Key Market Trends in theAntipsychotic Drugs Market Over the Coming Years?#_x000D_

Prominent organizations in the antipsychotic drug industry are concentrating on advancing medical products like subcutaneous atypical antipsychotic injections. These are more advanced than traditional oral pills and provide better patient compliance and effectiveness. Subcutaneous atypical antipsychotic injections, injected under the skin, are utilized for treating mental disorders, maintaining consistent blood levels, and enhancing symptom management. To illustrate, in April 2023, Teva Pharmaceutical Industries Ltd., a pharmaceutical firm based in Israel, and MedinCell SA, a French biological product manufacturer and pharmaceutical preparer, rolled out FDA-approved UZEDY. This is an extended-release injectable version of risperidone designed as a long-acting subcutaneous injection with flexible one to two-month dosing intervals. UZEDY leverages MedinCell’s signature SteadyTeq technology which ensures a consistent medication release, achieving therapeutic levels within 6–24 hours post-administration. In clinical evaluations, it showed up to an 80% decrease in the risk of schizophrenia relapse compared to placebo. UZEDY aims to tackle the adherence issues typically linked with oral antipsychotics that frequently cause relapses._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/antipsychotic-drugs-global-market-report_x000D_

_x000D_

#How Is the Antipsychotic Drugs Market Conceptually Defined?#_x000D_

Antipsychotic drugs are a class of medications used primarily to manage and treat symptoms of psychosis, which can include delusions, hallucinations, paranoia, and disordered thinking. Psychosis is commonly associated with psychiatric conditions such as schizophrenia, bipolar disorder, and severe depression. These medications are also sometimes referred to as neuroleptics or major tranquilizers._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18780_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model